March 1, 2004Expert Opinion on Pharmacotherapy
Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness
Why the study?
Does clopidogrel or the combination of aspirin and clopidogrel reduce the risk of serious vascular events compared to aspirin alone in patients at risk for atherothrombotic coronary artery disease?
Population
Patients at high risk of atherothrombotic coronary artery disease, including those with non-ST-segment…
Comparison
Aspirin, clopidogrel, or the combination of… vs Aspirin alone or placebo
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform antiplatelet selection in high-risk patients; leaves open optimal regimens in contemporary cohorts.
Structured PICO
Does clopidogrel or the combination of aspirin and clopidogrel reduce the risk of serious vascular events compared to aspirin alone in patients at risk for atherothrombotic coronary artery disease?
P
Population
Patients at high risk of atherothrombotic coronary artery disease, including those with non-ST-segment elevation acute coronary syndrome or undergoing percutaneous coronary intervention
I
Intervention
Aspirin, clopidogrel, or the combination of aspirin and clopidogrel
C
Comparator
Aspirin alone or placebo (implied for primary prevention)
O
Outcome
Serious vascular events (myocardial infarction, stroke or cardiovascular death)composite
Clopidogrel is a cost-effective alternative for patients intolerant to aspirin or at very high risk, and dual antiplatelet therapy is recommended for patients with NSTE-ACS or those undergoing PCI.
Cite This Study
Ho et al. (2004) studied this question.